Avant Diagnostics, based in Scottsdale, Arizona, is a
medical diagnostic company specializing in large panel biomarker screening.
OvaDx is the company’s first test, a sophisticated microarray-based way to
detect pre-symptomatic ovarian cancer by measuring the activation of the immune
system in blood samples in response to early stage ovarian tumor cell
development.
Identifying the variations of specific genes in the genome
is an expanding objective of genetic research, since variations are what define
individual characteristics, including disease states or a statistical
propensity for disease. Early detection of disease can provide options for
earlier treatments that may improve the patient’s chances of survival, as well
as their quality of life. It could also mean significant cost savings by
avoiding expensive late stage disease treatments.
OvaDx is an advanced microarray-based diagnostic test that
measures the activation of the immune system in response to ovarian tumor cell
development. It’s the market’s first large-panel screening test for ovarian
cancer, and can be used as an elective screen for women seeking greater
wellness, and for screening women at elevated risk for ovarian cancer. OvaDx
has indicated a high sensitivity and specificity for all types and stages of
ovarian cancer, including stage IA-IV borderline serous, clear cell,
endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma.
Clinicians will appreciate the following features of OvaDx:
• High sensitivity and specificity for all types and stages
of ovarian cancer
• Identifies stage I, II, III and IV disease markers in
patient samples
• Detects stage IA disease markers with ~80% sensitivity and
100% Specificity
• Multi-plexed microarray assay reads approximately 100
proteomic biomarkers
• Proteomic panel provides definitive real-time test results
• Microarray format reduces serum requirement to 0.1-0.25 ml
per sample run
• Arrayit Diagnostics, Inc. blood cards can also be used for
sample collection
• Fluorescence detection ensures high signal detectivity
• Test controls eliminate experimental false positives and
false negatives
• High-throughput format scales to any number of patient
samples
• Automated process permits large-scale (e.g. 1,000,000
sample+) screening
• Supplement OVA1® and other multi-analyte tests
• Supplement genetic tests including BRCA1 and BRCA2
• Screen patient sera from breast, cervical, uterine and
other cancer patients
• Test samples from patients with ovarian cysts and other
benign conditions
Avant recently announced the start of calibration testing in
preparation for the OvaDx validation study, to be used in support of a
pre-submission package for the FDA (U.S. Food and Drug Administration).
For more information on the company, visit https://avantdiagnostics.wordpress.com/
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment